4,248 Shares in Astera Labs, Inc. $ALAB Bought by Axxcess Wealth Management LLC

Axxcess Wealth Management LLC purchased a new position in shares of Astera Labs, Inc. (NASDAQ:ALAB) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 4,248 shares of the company’s stock, valued at approximately $384,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC grew its holdings in Astera Labs by 198.6% during the 1st quarter. Farther Finance Advisors LLC now owns 1,284 shares of the company’s stock worth $80,000 after acquiring an additional 854 shares in the last quarter. GAMMA Investing LLC grew its holdings in Astera Labs by 55.7% during the 1st quarter. GAMMA Investing LLC now owns 794 shares of the company’s stock worth $47,000 after acquiring an additional 284 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its holdings in Astera Labs by 9.4% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 4,946 shares of the company’s stock worth $295,000 after acquiring an additional 426 shares in the last quarter. Cherry Creek Investment Advisors Inc. grew its holdings in Astera Labs by 17.7% during the 1st quarter. Cherry Creek Investment Advisors Inc. now owns 3,547 shares of the company’s stock worth $212,000 after acquiring an additional 534 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. grew its holdings in Astera Labs by 63.8% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 13,906 shares of the company’s stock worth $830,000 after acquiring an additional 5,416 shares in the last quarter. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Insider Activity

In other Astera Labs news, Director Stefan A. Dyckerhoff sold 25,000 shares of the business’s stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $173.42, for a total transaction of $4,335,500.00. Following the completion of the transaction, the director directly owned 99,154 shares of the company’s stock, valued at $17,195,286.68. The trade was a 20.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Michael Truett Tate sold 100,000 shares of the business’s stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $171.38, for a total transaction of $17,138,000.00. Following the transaction, the chief financial officer directly owned 518,996 shares of the company’s stock, valued at $88,945,534.48. The trade was a 16.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,182,514 shares of company stock worth $202,298,671 over the last three months. Insiders own 12.50% of the company’s stock.

Wall Street Analysts Forecast Growth

ALAB has been the subject of several recent analyst reports. Northland Capmk lowered shares of Astera Labs from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 22nd. Evercore ISI raised their price objective on shares of Astera Labs from $104.00 to $215.00 and gave the stock an “outperform” rating in a report on Wednesday, August 6th. Wall Street Zen raised shares of Astera Labs from a “hold” rating to a “buy” rating in a report on Saturday. Morgan Stanley lifted their price target on shares of Astera Labs from $155.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, August 29th. Finally, Barclays reaffirmed an “overweight” rating and issued a $155.00 price target (up from $75.00) on shares of Astera Labs in a report on Thursday, August 7th. Fifteen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $162.06.

Astera Labs Stock Performance

NASDAQ ALAB opened at $159.80 on Friday. Astera Labs, Inc. has a one year low of $47.13 and a one year high of $262.90. The company has a 50-day simple moving average of $199.68 and a 200-day simple moving average of $128.30. The firm has a market capitalization of $26.56 billion, a PE ratio of 285.36, a price-to-earnings-growth ratio of 3.98 and a beta of 1.43.

Astera Labs (NASDAQ:ALAB) last posted its earnings results on Tuesday, August 5th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.11. The firm had revenue of $191.93 million during the quarter, compared to analyst estimates of $172.46 million. Astera Labs had a net margin of 16.54% and a return on equity of 9.53%. Astera Labs’s revenue was up 149.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.13 EPS. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. Equities analysts forecast that Astera Labs, Inc. will post 0.34 earnings per share for the current year.

About Astera Labs

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.